Pharmacogenetics of Asthma Medication in Children: Medication with Anti-inflammatory effects with special focus on Neutrophils.

Completed

Conditions: Asthma
10006436

Registration Number: NL-OMON41390

Lead Sponsor: niversiteit Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 1010

Inclusion Criteria

- Use R03 drugs
- Age between 4-12 years
- Parents able to speak, read and write Dutch language
- At least 2 years of medication history available in which the child filled >=1 prescriptions for any asthma drug (RO3) within the last 6 months and at least 2 prescriptions in the last 12-24 months;For PACMAN phase 2 we will select a subgroup of these patients;
- parents consented to be approached for future research
- child is 8 years or older
- child is adherent to ICS
- child is classified as a non-responder (case) or responder to asthma medication (control)

Exclusion Criteria

- child is younger than 8 years
- child does not use ICS
- child is not adherent to ICS
- consent is not obtained to be approached for future research during phase 1

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Study outcome:<br /><br>- treatment response.<br /><br>- biomarkers for therapy response<br /><br><br /><br>Study parameters:<br /><br>- genetic polymorphisms (SNPs)<br /><br>- patient characteristics (other than genetic factors)<br /><br><br /><br>We will focus on SNPs in genes involved in pharmacological asthma treatment<br /><br>pathways. To measure the treatment response and to make correctuin for<br /><br>confounders the parents are asked to fill in a questionnaire on symptoms,<br /><br>medication use, environmental factors etc. In addition we will assess whether<br /><br>we can measure the gut microbiome in children who remain uncontrolled despite<br /><br>treatment in a pilot study setting. </p><br>

Secondary Outcome Measures